No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products
(1997) In British Journal of Haematology 99(2). p.289-294- Abstract
- Immunomodulatory effects of various factor VIII and factor IX clotting factor concentrates (CFCs) and of albumin were evaluated by a sensitive assay measuring the incorporation of 3H-thymidine in phytohaemagglutinin-stimulated lymphocytes in the presence of monodansylthiacadaverine. In contrast to previous findings by others, we found lymphocyte transformation to be inhibited by all plasma-derived factor VIII concentrates at concentrations of 0.02, 0.2 and 2.0 IU/ml, including those purified by monoclonal antibodies (P < 0.05). Kryobulin TIM3 had the most pronounced effect. In addition, three plasma-derived human albumin preparations exerted a similar inhibitory effect as the factor VIII concentrates, whereas the corresponding... (More)
- Immunomodulatory effects of various factor VIII and factor IX clotting factor concentrates (CFCs) and of albumin were evaluated by a sensitive assay measuring the incorporation of 3H-thymidine in phytohaemagglutinin-stimulated lymphocytes in the presence of monodansylthiacadaverine. In contrast to previous findings by others, we found lymphocyte transformation to be inhibited by all plasma-derived factor VIII concentrates at concentrations of 0.02, 0.2 and 2.0 IU/ml, including those purified by monoclonal antibodies (P < 0.05). Kryobulin TIM3 had the most pronounced effect. In addition, three plasma-derived human albumin preparations exerted a similar inhibitory effect as the factor VIII concentrates, whereas the corresponding plasma-derived factor IX concentrates only manifested minor immunomodulatory effects. Of the recombinant preparations, only Recombinate exerted an inhibitory effect at 0.02 and 0.2 IU/ml, whereas both Kogenate and Recombinate decreased 3H-thymidine incorporation at 2.0 IU/ml (P = 0.01). No immunomodulatory effect at all was observed with r-VIII SQ, a new B-domain-deleted recombinant factor VIII preparation free from added albumin. The significance of this finding regarding immunological side-effects including inhibitor development remains to be evaluated, but this second-generation recombinant product opens up new and interesting perspectives yet to be explored. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1112228
- author
- Astermark, Jan LU ; Ekman, Maj LU and Berntorp, Erik LU
- organization
- publishing date
- 1997
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- immunomodulatory effects, clotting factor concentrates, lymphocyte transformation, albumin, factor VIII, factor IX
- in
- British Journal of Haematology
- volume
- 99
- issue
- 2
- pages
- 289 - 294
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:9375741
- scopus:0030724221
- ISSN
- 0007-1048
- DOI
- 10.1046/j.1365-2141.1997.4153222.x
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200), Clinical Coagulation Research Unit (013242510)
- id
- c5772556-c153-4aef-9abe-38edc84ccb53 (old id 1112228)
- date added to LUP
- 2016-04-01 11:56:25
- date last changed
- 2022-01-26 20:27:19
@article{c5772556-c153-4aef-9abe-38edc84ccb53, abstract = {{Immunomodulatory effects of various factor VIII and factor IX clotting factor concentrates (CFCs) and of albumin were evaluated by a sensitive assay measuring the incorporation of 3H-thymidine in phytohaemagglutinin-stimulated lymphocytes in the presence of monodansylthiacadaverine. In contrast to previous findings by others, we found lymphocyte transformation to be inhibited by all plasma-derived factor VIII concentrates at concentrations of 0.02, 0.2 and 2.0 IU/ml, including those purified by monoclonal antibodies (P < 0.05). Kryobulin TIM3 had the most pronounced effect. In addition, three plasma-derived human albumin preparations exerted a similar inhibitory effect as the factor VIII concentrates, whereas the corresponding plasma-derived factor IX concentrates only manifested minor immunomodulatory effects. Of the recombinant preparations, only Recombinate exerted an inhibitory effect at 0.02 and 0.2 IU/ml, whereas both Kogenate and Recombinate decreased 3H-thymidine incorporation at 2.0 IU/ml (P = 0.01). No immunomodulatory effect at all was observed with r-VIII SQ, a new B-domain-deleted recombinant factor VIII preparation free from added albumin. The significance of this finding regarding immunological side-effects including inhibitor development remains to be evaluated, but this second-generation recombinant product opens up new and interesting perspectives yet to be explored.}}, author = {{Astermark, Jan and Ekman, Maj and Berntorp, Erik}}, issn = {{0007-1048}}, keywords = {{immunomodulatory effects; clotting factor concentrates; lymphocyte transformation; albumin; factor VIII; factor IX}}, language = {{eng}}, number = {{2}}, pages = {{289--294}}, publisher = {{Wiley-Blackwell}}, series = {{British Journal of Haematology}}, title = {{No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products}}, url = {{http://dx.doi.org/10.1046/j.1365-2141.1997.4153222.x}}, doi = {{10.1046/j.1365-2141.1997.4153222.x}}, volume = {{99}}, year = {{1997}}, }